Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.051
Buy
RSI(14)
48.824
Neutral
STOCH(KDJ)(9,3,3)
26.025
Sell
ATR(14)
1.404
Low Volatility
CCI(14)
-86.493
Neutral
Williams %R
97.710
Oversold
TRIX(12,20)
2.832
Sell
StochRSI(14)
0.000
Sell
Search
NextCure Inc
NXTCAdd to Watchlist
4.145USD
-0.885-17.59%
Close 07-31 16:00（ET）Quotes delayed by 15 min
14.95MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-17.59%
5 Days
-2.24%
1 Month
+159.06%
6 Months
-61.80%
Year to Date
-70.79%
1 Year
-16.43%
Key Figures
4.910Open
5.080High
385.71KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
10.69%Turnover Ratio
5.030Prev. Close
4.100Low
1.31MTurnover
LossP/E Static
0.56P/B
0.00%Div Yield TTM
-104.01%ROA
15.74052wk High
0.68Volume Ratio
-55.65MNet Profit
3.61MShares
-16.8133EPS TTM
1.34Beta
-132.40%ROE
4.60052wk Low
19.48%Amplitude
--Gross Margin
14.95MMarket Cap
20.34Reward/Risk
8.24%Risk Rate
TradingKey Stock Score of NextCure Inc
Currency: USD Updated: 2026-07-31Key Insights
NextCure Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 88 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.50.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NextCure Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
NextCure Inc Highlights
StrengthsRisks
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Overvalued
The company’s latest PE is -0.25, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.75M shares, increasing 10.95% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 18.95.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
17.500
Target Price
+248.61%
Upside Space
NextCure Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
2
analysts
Buy
Current Rating
17.500
Target Price
+248.61%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
NextCure Inc
NXTC
2
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
4.947
Sell
MA10
4.807
Sell
MA20
4.261
Sell
MA50
3.805
Buy
MA100
7.270
Sell
MA200
9.500
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
NextCure Inc Info
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Ticker SymbolNXTC
CompanyNextCure Inc
CEORichman (Michael S)
Websitehttps://www.nextcure.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of NextCure Inc (NXTC)?
The current price of NextCure Inc (NXTC) is 4.10.
What is the symbol of NextCure Inc?
The ticker symbol of NextCure Inc is NXTC.
What is the 52-week high of NextCure Inc?
The 52-week high of NextCure Inc is 15.74.
What is the 52-week low of NextCure Inc?
The 52-week low of NextCure Inc is 4.60.
What is the market capitalization of NextCure Inc?
The market capitalization of NextCure Inc is 14.79M.
Is NextCure Inc (NXTC) currently rated as Buy, Hold, or Sell?
According to analysts, NextCure Inc (NXTC) has an overall rating of Buy, with a price target of 17.50.
What is the Earnings Per Share (EPS TTM) of NextCure Inc (NXTC)?
The Earnings Per Share (EPS TTM) of NextCure Inc (NXTC) is -19.65.